CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express

Aug 27

CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its investigational SYH2092 injection has obtained approval from China’s National Medical Products Administration to enter clinical trials.

SYH2092 is described as a highly potent amylin receptor agonist engineered for enhanced agonistic activity and an extended in-vivo half-life through optimized fatty-acid modification. The design aims to translate into durable weight-loss efficacy with a manageable tolerability profile.

In preclinical evaluations, SYH2092 demonstrated: • Higher receptor agonistic activity than several amylin analogues currently in development. • Strong weight-reduction effects and prolonged maintenance of weight loss. • Synergistic efficacy when combined with CSPC Pharma’s proprietary GLP-1/GIP dual-biased agonist, increasing both the magnitude and duration of weight reduction.

According to the company, the candidate has the potential to deliver meaningful clinical benefits in weight management for obese patients and to improve glycaemic control in adults with type 2 diabetes mellitus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1196349428"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196349428\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196349428?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196349428","market":"hk","top_or_hot":-1,"title":"CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its investigational SYH2092 injection has obtained approval from China’s National Medical Products Administration to enter clinical trials.</p>\n<p>SYH2092 is described as a highly potent amylin receptor agonist engineered for enhanced agonistic activity and an extended in-vivo half-life through optimized fatty-acid modification. The design aims to translate into durable weight-loss efficacy with a manageable tolerability profile.</p>\n<p>In preclinical evaluations, SYH2092 demonstrated:\n• Higher receptor agonistic activity than several amylin analogues currently in development.  \n• Strong weight-reduction effects and prolonged maintenance of weight loss.  \n• Synergistic efficacy when combined with CSPC Pharma’s proprietary GLP-1/GIP dual-biased agonist, increasing both the magnitude and duration of weight reduction.</p>\n<p>According to the company, the candidate has the potential to deliver meaningful clinical benefits in weight management for obese patients and to improve glycaemic control in adults with type 2 diabetes mellitus.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-27 18:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its investigational SYH2092 injection has obtained approval from China’s National Medical Products Administration to enter clinical trials.</p>\n<p>SYH2092 is described as a highly potent amylin receptor agonist engineered for enhanced agonistic activity and an extended in-vivo half-life through optimized fatty-acid modification. The design aims to translate into durable weight-loss efficacy with a manageable tolerability profile.</p>\n<p>In preclinical evaluations, SYH2092 demonstrated:\n• Higher receptor agonistic activity than several amylin analogues currently in development.  \n• Strong weight-reduction effects and prolonged maintenance of weight loss.  \n• Synergistic efficacy when combined with CSPC Pharma’s proprietary GLP-1/GIP dual-biased agonist, increasing both the magnitude and duration of weight reduction.</p>\n<p>According to the company, the candidate has the potential to deliver meaningful clinical benefits in weight management for obese patients and to improve glycaemic control in adults with type 2 diabetes mellitus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1196349428","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196349428","pubTimestamp":1787826454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its investigational SYH2092 injection has obtained approval from China’s National Medical Products Administration to enter clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团医药 SYH2092 获得 NMPA 批准，SYH2092 是一种针对肥胖和 2 型糖尿病的长效胰淀素受体激动剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) announced that its investigational SYH2092 injection has obtained approval from China’s National Medical Products Administration to enter clinical trials.\nSYH2092 is described as a highly potent amylin receptor agonist engineered for enhanced agonistic activity and an extended in-vivo half-life through optimized fatty-acid modification. The design aims to translate into durable weight-loss efficacy with a manageable tolerability profile.\nIn preclinical evaluations, SYH2092 demonstrated:\n• Higher receptor agonistic activity than several amylin analogues currently in development.  \n• Strong weight-reduction effects and prolonged maintenance of weight loss.  \n• Synergistic efficacy when combined with CSPC Pharma’s proprietary GLP-1/GIP dual-biased agonist, increasing both the magnitude and duration of weight reduction.\nAccording to the company, the candidate has the potential to deliver meaningful clinical benefits in weight management for obese patients and to improve glycaemic control in adults with type 2 diabetes mellitus.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}